Chugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 52-Week High – Here’s What Happened

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $26.00 and last traded at $24.76, with a volume of 1000911 shares. The stock had previously closed at $24.49.

Chugai Pharmaceutical Stock Down 1.5 %

The stock has a market cap of $77.64 billion, a price-to-earnings ratio of 34.71 and a beta of 0.89. The stock’s fifty day moving average is $23.74 and its 200-day moving average is $19.55.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.22 earnings per share (EPS) for the quarter. The company had revenue of $2.03 billion during the quarter. Chugai Pharmaceutical had a net margin of 32.68% and a return on equity of 21.45%. As a group, equities research analysts predict that Chugai Pharmaceutical Co., Ltd. will post 0.78 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.